
This study aims to elucidate a potential gene target for which an approved drug is available and to reveal further the function and underlying mechanism of the candidate gene. The study identified that ryanodine receptor 2 (RyR2) expression was upregulated in KRAS‐mutant mCRC and that this promoted cancer cell metastasis. High expression of RyR2 predicts poor survival in our patient cohort. Analysis of expression profiles upon RyR2 knockdown and inhibition reveals a set of metastasis‐related molecules and identifies the BTB domain and CNC homolog 1 (BACH1) as the main transcription factor regulated by RyR2. This study provides evidence that the RyR2/ROS/BACH1 axis may be a potential target to intervene with CRC metastasis.
Like
Save
Share